论文信息 - Cancer Clinical Investigators Should Converge with Pharmacometricians

Cancer Clinical Investigators Should Converge with Pharmacometricians

The applied quantitative science pharmacometrics has significantly enhanced cancer therapeutics development. Pharmacometrics is now improving our understanding of complex diagnostics. Through the concept of convergence and methods of quantitative and systems pharmacology, pharmacometrics is poised to interconnect mathematical models of disease and therapy to advance cancer care. See related article by Colomban et al., p. 5342

Michael L Maitland | Roisin E O'Cearbhaill | Jogarao Gobburu

[1] P. Disaia,et al. CA 125 kinetics: a cost-effective clinical tool to evaluate clinical trial outcomes in the 1990s. , 1996, American journal of obstetrics and gynecology.

[2] I. Ray-Coquard,et al. Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study , 2019, Clinical Cancer Research.

[3] J. Samet,et al. From the Food and Drug Administration. , 2002, JAMA.

[4] Lawrence J Lesko,et al. Quantitative disease, drug, and trial models. , 2009, Annual review of pharmacology and toxicology.

[5] Sanjiv S Gambhir,et al. Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations , 2011, Science Translational Medicine.

[6] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983, The New England journal of medicine.

[7] R. Bast,et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. , 1983 .